Whereas inhibition of NHEJ by targeting DNA-PKcs needs further preclinical investigation in vivo, PARP inhibitors as chemo-sensitizers for temozolomide and irinotecan are already being investigated in clinical trials for Ewing sarcoma and other cancers. This evidence concerns the gene PRKDC and Ewing sarcoma.